SynthesisHepatology international2024
Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis.
Synthesis in Hepatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Chinese expert consensus on clinical practice of chronic hepatitis B functional (clinical) cure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Guideline
- Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.Nature medicine · 2026Trial
- Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks.Hepatology international · 2025Trial
- Short-term pegylated interferon alpha in chronic HBV patients with ultra-low HBsAg: a retrospective study.Frontiers in cellular and infection microbiology · 2025Trial
- Article
- Leveraging machine learning to identify optimal patient populations for PEG-IFN therapy in CHB and constructing nomogram models of interferon response: a 48-week follow-up study.BMC gastroenterology · 2026Article
- Dynamic changes in TREX1 and LGALS9 mRNA levels in PBMCs predict HBsAg clearance and treatment responses to Peg-IFN-α therapy in HBeAg-negative chronic hepatitis B patients.Virology journal · 2026Article
- Hepatitis B virus functional cure in persons with HIV: what are the predictors and which novel markers are useful?Current opinion in HIV and AIDS · 2026Review
- Traditional and Novel Virologic Markers for Functional Cure and HBeAg Loss with Pegylated Interferon in Chronic Hepatitis B: A Systematic Review and Meta-analysis.Journal of clinical and translational hepatology · 2026Article
- Comparative effectiveness of tenofovir versus entecavir combined with peginterferon Alfa-2b for functional cure in HBeAg-negative chronic hepatitis B: a propensity score-matched analysis.BMC infectious diseases · 2026Article
- ENPP1 and IFIT2 in PBMCs as early predictive biomarkers for HBsAg clearance and responses to Peg-IFN-α in HBeAg-negative chronic hepatitis B patients.Frontiers in immunology · 2026Article
- The clinical significance and optimization strategies of HBeAg seroclearance in chronic hepatitis B treatment.Frontiers in cellular and infection microbiology · 2026Review
- Efficacy of pegylated interferon alpha in treating postpartum women with chronic hepatitis B virus infection: a multicenter prospective study.Frontiers in cellular and infection microbiology · 2026Article
- Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon.Hepatology international · 2025Article
- Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study.Virology journal · 2025Article
- Article
- Dynamic predicting hepatitis B surface antigen decline rate during treatment for patients with chronic hepatitis B.Infectious Disease Modelling · 2025Article
- [Research progress on predictive indicators of a clinical cure for chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- [Clinical cure and safe drug withdrawal in chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection.Drug design, development and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
aimsThe efficacy of achieving HBsAg clearance through pegylated interferon (PEG-IFNα) therapy in patients with chronic hepatitis B (CHB) remains uncertain, especially regarding the probability of achieving functional cure among patients with varying baseline HBsAg levels. We aimed to investigate the predictive value of HBsAg quantification for HBsAg seroclearance in CHB patients undergoing PEG-IFNα treatment.
methodsA systematic search was conducted in PubMed, Embase, and the Cochrane Library up to January 11, 2022. Subgroup analyses were performed for HBeAg-positive and HBeAg-negative patients, PEG-IFNα monotherapy and PEG-IFNα combination therapy, treatment-naive and treatment-experienced patients, and patients with or without liver cirrhosis.
resultsThis predictive model incorporated 102 studies. The overall HBsAg clearance rates at the end of treatment (EOT) and the end of follow-up (EOF) were 10.6% (95% CI 7.8-13.7%) and 11.1% (95% CI 8.4-14.1%), respectively. Baseline HBsAg quantification was the most significant factor. According to the model, it is projected that when baseline HBsAg levels are 100, 500, 1500, and 10,000 IU/ml, the HBsAg clearance rates at EOF could reach 53.9% (95% CI 40.4-66.8%), 32.1% (95% CI 24.8-38.7%), 14.2% (95% CI 9.8-18.8%), and 7.9% (95% CI 4.2-11.8%), respectively. Additionally, treatment-experienced patients with HBeAg-negative status, and without liver cirrhosis exhibited higher HBsAg clearance rates after PEG-IFNα treatment.
conclusionA successful predictive model has been established to predict the achievement of functional cure in CHB patients receiving PEG-IFNα therapy.
Indexed as
Identifiers
38913149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.